A Phase 1 interventional study of Subcutaneous (SC) Etentamig and Intravenous (IV) Etentamig in Multiple Myeloma, sponsored by AbbVie. Active, not recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.
Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 9th largest by enrollment, is one of 2 that started in 2024, is one of 4 in phase 1, and was the 5th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, Israel and 3 more countries
Ages 18+
AbbVie · Sites in United States, Canada, Denmark and 4 more countries
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 3
First in 2019; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 235 across the 10 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
40 studies in Multiple Myeloma by AbbVie: 7 open now, 17 under way, 5 of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 24th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2024, is one of 18 in phase 1, reaches primary completion later than 4 of the 16 other live ones, and was the 34th registered.
AbbVie’s Multiple Myeloma studies by the year they started, since 2005.
1 of the studies testing etentamig in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06223516AbbVieStudy of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing etentamig in Multiple Myeloma, from their registry updates:
Among AbbVie’s 40 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of Etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM.
Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusion in Arm A and SC injections of ABBV-383 in Arm B. Around 55 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 15 sites across the world
In Arm A participants will receive one of two doses of Etentamig (ABBV-383) as an SC injection and (IV) infusions, during the 151 week study duration. In Arm B, participants will receive the selected dose from Arm A as SC injections, during the 151 week study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Received B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose A of Etentamig as a subcutaneous (SC) injection and intravenous (IV) infusions, during the 151 week study duration.
Drug: Subcutaneous (SC) Etentamig · Drug: Intravenous (IV) Etentamig
Participants will receive Dose B of Etentamig as an SC injection and IV infusions, during the 151 week study duration.
Drug: Subcutaneous (SC) Etentamig · Drug: Intravenous (IV) Etentamig
Participants will receive the selected dose from Arm A of Etentamig as SC injections, during the 151 week study duration.
Drug: Subcutaneous (SC) Etentamig
SC Injection
IV Infusion
Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events
Cytokine Release Syndrome events will be graded using American Society for Transplantation and Cellular Therapy (ASTCT), with a higher grade indicating higher severity.
Time frame: Up to 2 cycles (56 days)
Percentage of Participants Experiencing Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events
ICANS events will be graded using ASTCT, with a higher grade indicating higher severity.
Time frame: Up to 2 cycles (56 days)
Maximum Observed Concentration (Cmax) of ABBV-383
Cmax of ABBV-383.
Time frame: Up to 32 weeks
Time to Cmax (Tmax) of ABBV-383
Tmax of ABBV-383.
Time frame: Up to 32 weeks
Trough Concentration (Ctrough) of ABBV-383
Ctrough of ABBV-383.
Time frame: Up to 32 weeks
Area Under the Plasma Concentration-time Curve (AUC) of ABBV-383
AUC of ABBV-383.
Time frame: Up to 24 weeks
Overall Response Rate (ORR)
The ORR is defined as the percentage of participants who achieve a best overall response of confirmed PR or better determined by international myeloma working group (IMWG) criteria, prior to the initiation of subsequent myeloma therapy.
Time frame: Up to 24 months
Percentage of Participants Achieving Stringent Complete Response (sCR),
sCR is defined as participants achieving negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in bone marrow, normal free light chain (FLC) ratio, and Absence of clonal cells in bone marrow by immunohistochemistry.
Time frame: Up to 24 months
Percentage of Participants Achieving Complete Response (CR)
CR is defined as participants achieving negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, \< 5% plasma cells in bone marrow, and for participants in whom the only measurable disease is by serum FLC levels, a normal FLC ratio.
Time frame: Up to 24 months
Percentage of Participants Achieving Very Good Partial Response (VGPR)
VGPR is defined as participants achieving serum and urine M-protein detectable by immunofixation but not on electrophoresis, \>= 90% reduction in serum M-protein plus urine, and for participants in whom the only measurable disease is by serum FLC levels, \>= 90% decrease in the difference between involved and uninvolved FLC levels.
Time frame: Up to 24 months
Percentage of Participants Achieving Partial Response (PR)
PR is defined as participants achieving \>= 50% reduction of serum M-protein, reduction in 24-hour urinary M-protein by \>= 90% as noted in the protocol, \>= 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline.
Time frame: Up to 24 months
Duration of Response (DoR)
DoR will be defined as the time from the date of first response \[partial response (PR) + VGPR + complete response (CR) + stringent complete response (sCR)\] to the earliest occurrence of progressive disease, or death, whatever occurs first.
Time frame: Up to 24 months
Progression Free Survival (PFS)
PFS is defined as the duration from the date of randomization to the date of confirmed disease progression (PD) per international myeloma working group (IMWG) criteria, or death, whichever occurs first.
Time frame: Up to 24 months
Time to Response (TTR)
TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by IMWG criteria.
Time frame: Up to 24 months
Immunogenicity of ABBV-383 as Determined by Anti-Drug Antibodies (ADAs)
Incidence and concentration of ADAs.
Time frame: Up to 27 months
Immunogenicity of ABBV-383 as Determined by Neutralizing Anti-Drug Antibodies (NAbs)
Incidence and concentration of NAbs.
Time frame: Up to 27 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 32 months after the start.
Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 32 months is below that.
Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etentamig